Prediction of Toxicity, Sensory Responses and Biological Responses with the Abraham Model by William E. Acree et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
12 
Prediction of Toxicity, Sensory Responses and 
Biological Responses with the Abraham Model 
William E. Acree, Jr.1, Laura M. Grubbs1 and Michael H. Abraham2 
1University of North Texas, 
2University College London,  
1United States 
2United Kingdom 
1. Introduction 
Modern drug testing and design includes experimental in vivo and in vitro measurements, 
combined with in silico computations that enable prediction of the drug candidate’s ADMET 
(adsorption, distribution, metabolism, elimination and toxicity) properties in the initial 
stages of drug discovery. Recent estimates place the discovery and development cost of a 
small drug molecule close to US $1.3 billion, from the time of conception to the time when 
the drug finally reaches the market place. Less than one-fourth of conceived drug candidates 
proceed to clinical trial stage testing, and of the compounds that enter clinical development 
less than one-tenth actually receive government approval. Reasons for the low success 
percentage include poor efficacy, low solubility, unsatisfactory bioavailability, unfavorable 
pharmacokinetic properties, toxicity concerns and drug-drug interactions, degradation and 
poor shelf-life stability. Unfavorable pharmacokinetic and ADME properties, toxicity and 
adverse side effects account for up to two-thirds of drug failures.  
Safety evaluation of drug candidates is crucial in the early stages of drug discovery and 
development. For drug development, safety requires that the potential drug molecule have 
sufficient selectivity for the desired target receptor so that an adequate dose range can be 
found where the intended pharmacological action is essentially the only physiological effect 
exhibited by the drug candidate. Pharmaceutical compounds often exhibit the desired 
therapeutic action at one concentration range, but may be quite toxic or even lethal at higher 
dosages and concentrations. Drug induced liver injury (DILI) is the most frequent reason for 
discontinuation of new drug candidates. Drug-induced liver injuries are classified as 
predicted/intrinsic or idiosyncratic depending upon whether the injury is dose dependent. 
Predictable DILIs are dose-dependent, and the injury is largely reversible once the 
medication is discontinued. Idiosyncratic DILIs, on the other hand, are independent of drug 
dosage level and believed to be related in part to individual’s hypersensitivity or immune 
system reactions to the medication. Idiosyncratic DILIs depend upon the individual’s 
potential genetic and epigenetic constitution, and immunological responses (Ozer et al., 
2010). Examples of drug and/or drug candidates that either failed in late stage clinical 
testing or were removed from the market because of drug-induced liver injury concerns 
include: ximelagatran (an anticoagulant that was promoted extensively as a replacement for 
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warfarin, withdrawn in from US market in 2006); troglitazone (an anti-diabetic and anti-
inflammatory drug, withdrawn from the UK market in 1997 and US market in 2000); 
ebrotidine (an H2-reciptor antagonist, marketed in Spain in 1997, withdrawn from the 
market in 1998); ticrynafen (a diuretic drug used in treatment of hypertension, withdrawn 
from US market in 1979); benoxaprofen (a nonsteroidal anti-inflammatory drug, withdrawn 
from US market in 1982); ibufenac (nonsteroidal anti-inflammatory drug used for the 
treatment of Rheumatoid arithritis, withdrawn from UK market in 1970) and bromfenac (a 
nonsteroidal anti-inflammatory drug introduced in 1997 as a short-term analgesic for 
orthopedic pain, withdrawn from the market in 1998) (Lamment et al., 2008; Andrade et al., 
1999; Goldkind and Laine, 2006). Other drugs, such as valproic acid, ketoconazole, nicotinic 
acid, rifampin, chlorzoxazone, isoniazid, dantrolene, nefazodone, telethromycin, nevirapine, 
atomoxetine and inflixmab have received strong heptatoxicity warnings from the U.S. Food 
and Drug Administration (Lamment et al., 2008). Sibutramine and phenylpropanolamine, 
used in the treatment of obesity, were removed from the U.S. market due to adverse effects 
associated with cardiovascular disease and hemorrhagic stroke, respectively. (Chaput and 
Tremblay, 2010). Additional drugs withdrawn from the market for cardiovascular toxicities 
and concerns include: rotecoxib (used to relieve acute pain and symptoms of chronic 
inflammation, removed from market in 2005) and valdecoxib (used to relieve acute pain and 
symptoms of chronic inflammation, removed from market in 2005) (Shi and Klotz, 2008).  
Toxicity screening identifies drug candidates that exhibit predictable/intrinsic drug-induced 
liver injury. Idiosyncratic DILI occurs infrequently and only in treated patients which are 
highly susceptible to the given pharmaceutical compound. Conventional preclinical safety 
testing is not the best method to detect idiosyncratic DILI. Fourches and coworkers (2010) 
examined the possibility of using laboratory test animals as viable means to screen drug 
candidates for possible drug-induced liver injuries. The authors compiled a data set of 951 
compounds reported to induce a wide range of liver effects in humans and in different 
animal species. Of the 951 compounds considered, 650 had been identified as causing liver 
effects in humans, 685 had been reported in the literature as causing liver effects in rodents, 
and only 166 had shown liver effects in nonrodents. The concordance between two species, 
CONC(species A, species) was defined as 
 
( ) ( )
( )
Toxic for both Aand B Nontoxic for both Aand B
CONC species A speciesB
Totalnumber of compoundsstudied
   (1) 
as the number of compounds that exhibited toxicity for both animal species plus the number 
of compounds that showed notoxicity for both animal species divided by the total number 
of compounds considered. Equation 1 was applied to the liver effect data gathered from the 
published literature. The authors found a relatively low concordance of between 39 % to 44 
% between different species – for human + rodents the concordance was equal to 44.2 % 
((402 + 18)/951); and for human + nonrodents that concordance was equal to 39.9 % 
((122+257)/951). Animal testing, while informative, does not necessarily provide an accurate 
indication of the pharmaceutical compound’s likelihood to produce a liver effect in humans. 
For the concordance calculations it was assumed that the pharmaceutical compound had 
been tested on all three species groups. The above calculations further underscore the 
importance of finding suitable testing methods and models for use in drug discovery.  
Drug safety considerations also include unwanted side effects, and the impact that the 
pharmaceutical product will have on environment. A significant fraction of the 
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pharmaceutically-active compounds sold each year find their way into the environment as 
the result of human/animal urine and feces excretion (excreted unchanged drugs or as drug 
metabolites), direct disposal of unused household drugs by flushing into sewage systems, 
accidental spills and releases from manufacturing production sites, and underground 
leakage from municipal sewage systems and infrastructures. Dietrich and coworkers (2010) 
recently examined the environmental impact that four pharmaceutical compounds 
(carbamazepine, diclofenac, 17α-ethinylestradiol and metoprolol) had on the growth and 
reproduction of Daphnia Magna after exposure to the individual drugs and drug mixtures at 
environmentally relevant concentrations. The authors found that effects were still detectable 
even several generations after first exposure to the pharmaceutical compound. The Daphnia 
Magna had not developed complete resistance to the compound. In the case of metoprolol, 
both the body length of the females at first reproduction and the number of offspring per 
female were significantly less than the control group. The same body length pattern was 
observed for females in the third and fourth generations. No difference in female body 
length was observed in the first, second and fifth generations. The number of offspring per 
female was also reduced for the fourth generation. Experimental data further revealed that 
drugs acting in combination can lead to impairments that are not predicted by the response 
to single substances alone. The authors noted that aquatic organisms may not evolve a total 
resistance to pharmaceuticals in natural aquatic systems, presumably due to high fitness 
costs. One cannot exclude the potential long-term harmful effects that pharmaceuticals 
might have on the environment. The Chapter will focus on the predicting the toxicity, 
sensory response and biological response of organic and drug molecules using the Abraham 
solvation parameter model.  
2. Abraham solvation parameter model 
The Abraham general solvation model is one of the more useful approaches for the analysis 
and prediction of the adsorption, distribution and toxicological properties of potential drug 
candidates. The method relies on two linear free energy relationships (lfers), one for transfer 
processes occurring within condensed phases (Abraham, 1993a,b; Abraham et al., 2004): 
 SP = c + e · E + s · S + a · A + b · B + v · V (2) 
and one for processes involving gas-to-condensed phase transfer 
 SP = c + e · E + s · S + a · A + b · B + l · L (3) 
The dependent variable, SP, is some property of a series of solutes in a fixed phase, which in 
the present study will include the logarithm of drug’s water-to-organic solvent (log P) and 
blood-to-tissue partition coefficients, the logarithm of the drug’s molar solubility in an 
organic solvent divided by its aqueous molar solubility (log Csolute,org/Csolute,water), the 
logarithm of the drug’s plasma-to-milk partition coefficient, percent human intestinal 
absorption and the logarithm of the kinetic constant for human intestinal absorption, and 
the logarithm of the human skin permeability coefficient (log kp). The independent 
variables, or descriptors, are solute properties as follows: E and S refer to the excess molar 
refraction and dipolarity/polarizability descriptors of the solute, respectively, A and B are 
measures of the solute hydrogen-bond acidity and basicity, V is the McGowan volume of 
the solute and L is the logarithm of the solute gas phase dimensionless Ostwald partition 
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coefficient into hexadecane at 298 K. For a number of partitions into solvents that contain 
large amounts of water at saturation, an alternative hydrogen bond basicity parameter, Bo, is 
used for specific classes of solute: alkylpyridines, alkylanilines, and sulfoxides. Several of 
the published Abraham model equations for predicting the toxicity of organic compounds 
to different aquatic organisms use the Bo solute descriptor, rather than the B descriptor. 
Equations 1 and 2 contain the following three quantities: (a) measured solute properties; (b) 
calculated solute descriptors; and (c) calculated equation coefficients. Knowledge of any two 
quantities permits calculation of the third quantity through the solving of simultaneous 
equations and regression analysis. Solute descriptors are calculated from measured partition 
coefficient (Psolute,system), chromatographic retention factor (k’) and molar solubility 
(Csolute,solvent) data for the solutes dissolved in partitioning systems and in organic solvents 
having known equation coefficients. Generally partition coefficient, chromatographic 
retention factor and molar solubility measurements are fairly accurate, and it is good 
practice to base the solute descriptor computations on observed values having minimal 
experimental uncertainty. The computation is depicted graphically in Figure 1 by the 
unidirectional arrows that indicate the direction of the calculation using the known equation 
coefficients that connect the measured and solute descriptors. Measured Psolute,system and 
Csolute,solvent values yield solute descriptors. The unidirectional red arrows originating from 
the center solute descriptor circle represent the equation coefficients that have been reported 
for nasal pungency, aquatic toxicity, upper respiratory irritation and inhalation anesthesia 
Abraham model correlations. Plasma-to-milk partition ratio predictions are achieved 
(Abraham et al., 2009a) through an artificial neural network with five inputs, 14 nodes in the 
hidden layer and one node in the output layer. Linear analysis of the plasma-to-milk 
partition ratios for 179 drugs and hydrophobic environmental pollutants revealed that drug 
molecules preferentially partition into the aqueous and protein phases of milk. Hydrophobic 
environmental pollutants, on the other hand, partition into the fat phase.  
 
 
Fig. 1. Outline illustrating the calculation of Abraham solute descriptors from experimental 
partition coefficient and solubility data, and then using the calculated values to estimate 
sensory and biological responses, such as toxicity of organic chemicals to aquatic organisms, 
Draize eye scores, convulsant activity of inhaled vapors, upper respiratory irritation in mice, 
and inhalation anesthesia in rats and mice. 
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Prediction of the fore-mentioned toxicities, and sensory and biological responses does 
require a prior knowledge of the Abraham solute descriptors for the drug candidate of 
interest. The descriptors E and V are quite easily obtained. V can be calculated from atom 
and bond contributions as outlined previously (Abraham and McGowan, 1987). The atom 
contributions are given in Table 1; note that the numerical values are in cm3 mol-1. A value 
of 6.56 cm3 mol-1 is subtracted for each bond in the molecule; irrespective of whether the 
bond is a single, double or triple bond. For complicated molecules it is time consuming to 
count the number of bonds, Bn, but this can be calculated from the algorithm given by 
Abraham (1993a) 
 Bn = Nt –1 + R   (4)  
where Nt is the total number of atoms in the molecule and R is the number of rings. 
 
C 16.35 
 
N 14.39 
 
O 12.43 
Si 26.83 P 24.87 S 22.91 
Ge 31.02 As 29.42 Se 27.81 
Sn 39.35 Sb 37.74 Te 36.14 
Pb 43.44 Bi 42.19   
      
H 8.71 He 6.76 B 18.32 
F 10.48 Ne 8.51 Hg 34.00 
Cl 20.95 Ar 19.00   
Br 26.21 Kr 24.60   
I 34.53 Xe 32.90   
  Rn 38.40   
Table 1. Atom contributions to the McGowan volume, in cm3 mol-1 
Once V is available, E can be obtained from the compound refractive index at 20oC. If the 
compound is not liquid at room temperature or if the refractive index is not known the latter 
can be calculated using the freeware software of Advanced Chemistry Development (ACD). 
An Excel spreadsheet for the calculation of V and E from refractive index is available from 
the authors. Since E is almost an additive property, it can also be obtained by the summation 
of fragments, either by hand, or through a commercial software program (ADME Boxes, 
2010). The remaining four descriptors S, A, B, and L can be determined by regression 
analysis of experimental water-to-organic solvent partition coefficient data, 
chromatographic retention factor data, and molar solubility data in accordance to Eqns 1 
and 2. Solute descriptors are available for more than 4,000 organic, organometallic and 
inorganic solutes. Large compilations are available in one published review article 
(Abraham et al., 1993a), and in the supporting material that has accompanied several of our 
published papers (Abraham et al., 2006; Abraham et al., 2009b; Mintz et al., 2007).  
Experimental data-based solute descriptors have been obtained for a number of 
pharmaceutical compounds, for example 230 compounds in an analysis of blood-brain 
distribution (Abraham et al., 2006). Zissimos et al. (2002a) calculated the S, A and B solute 
descriptors of thirteen pharmaceutical compounds (propranolol, tetracaine, papaverine, 
trytamine, diclorfenac, chloropromazine, ibuprofen, lidocaine, deprenyl, desipramine, 
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fluoxetine, procaine, and miconazole) from measured water-to-octanol, water-to-
chloroform, water-to-cyclohexane and water-to-toluene partition coefficient data. Equation 
coefficients for the four water-to-organic solvent partition coefficients were known. Four 
mathematical methods based on the Microsoft Solver Progam, the Triplex Program, 
Descfit/SIMPLEX minimization and Reverse Regression were investigated. The authors 
(Zissimos et al., 2002b) later illustrated the calculation methods using experimental data 
from seven high performance liquid chromatographic systems. Solute descriptors of 
acetylsalicylic acid (Charlton et al., 2003), naproxen (Daniels et al., 2004a), ketoprofen 
(Daniels et al., 2004b) and ibuprofen (Stovall et al., 2005) have been calculated based on the 
measured solubilities of the respective drugs in water and in organic solvents.  
Abraham model correlations for predicting blood-to-body organ/tissue partition 
coefficients and the chemical toxicity of organic compounds towards aquatic organisms 
involve chemical transfer between two condensed phases. Predictive expressions for such 
solute properties do not contain the Abraham model L solute descriptor. There are however 
published Abraham model correlations for estimating important sensory and biology 
responses (such as convulsant activity of inhaled vapors, upper respiratory irritation in 
mice, inhalation anesthesia in rats and in mice) that do involve solute transfer from the gas 
phase. To calculate the L solute descriptor one must convert water-to-organic solvent 
partition coefficient data, P, into gas-to-organic solvent partition coefficients, K, 
 Log K = log P + log Kw (5) 
and water-to-organic solvent solubility ratios, Csolute,organic/Csolute,water, into gas-to-organic 
solvent solubility ratios, Csolute,organic/Csolute,gas, 
 Csolute,organic/Csolute,gas = Csolute,organic/Csolute,water * Csolute,water/Csolute,gas (6) 
where Csolute,water/Csolute,gas is the gas-to-water partition coefficient, usually denoted as Kw. 
The water-to-organic solvent and gas-to-organic solvent partition coefficient equations are 
combined in the solute descriptor computations. If log Kw is not known, it can be used as 
another parameter to be determined. This increases the number of unknowns from four (S, 
A, B and L) to five (S, A, B, L, and Kw), but the number of equations is increased 
significantly as well. Numerical values of the four solute descriptors and Kw can be easily 
calculated Microsoft Solver. The computations are described in greater detail elsewhere 
(Abraham et al., 2004; Abraham et al., 2010). The calculated value of the L descriptor can be 
checked against an Abraham model correlation for estimating the L solute descriptor 
 L = – 0.882 + 1.183 E + 0.839 S + 0.454 A + 0.157 B + 3.505 V (7) 
  (N = 4785, SD = 0.31, R2 = 0.992, F = 115279) 
from known values of E, S, A, B and V. Van Noort et al. (2010) cited a personnel 
communication from Dr. Abraham as the source of Eqn. 7. If one is unable to locate 
sufficient experimental data for performing the fore-mentioned regression analysis, 
commercial software (ADME Boxes, version*, 2010) is available for estimating the molecular 
solute descriptors from the structure of the compound. Several correlations (Jover et al., 
2004; Zissimos et al., 2002; Lamarche et al., 2001; Platts et al., 1999; Platts et al., 2000) have 
been reported for calculating the Abraham solute descriptors from the more structure-
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based, topological-based and/or quantum-based descriptors used in other QSAR and LFER 
treatments.  
3. Presence and toxicity of pharmaceutical compounds in the environment 
A significant fraction of the pharmaceutically-active compounds sold each year find their 
way into the environment as the result of human/animal urine and feces excretion (excreted 
unchanged drugs or as drug metabolites), direct disposal of unused household drugs by 
flushing into sewage systems, accidental spills and releases from manufacturing production 
sites, and underground leakage from municipal sewage systems and infrastructures. While 
most pharmaceutical compounds are designed to target specific metabolic pathways in 
humans and domestic animals, their action on non-target organisms may become 
detrimental even at very low concentrations. The occurrence of pharmaceutical residues and 
metabolites in the environment is a significant public and scientific concern. If not 
addressed, pharmaceutical pollution will become even a bigger problem as the world’s 
increasing and aging population purchases more prescription and more self-prescribed 
over-the-counter medicines to improve the quality of life.  
There have been very few published studies that have attempted to estimate the quantity of 
each pharmaceutical compound that will be released each year into the environment. Escher 
and coworkers (2011) evaluated the ecotoxicological potential of the 100 pharmaceutical 
compounds expected to occur in highest concentration in the wastewater effluent from both a 
general hospital and a psychiatric center in Switzerland. The authors based the calculated drug 
concentrations on the hospital’s records of the drugs administered in 2007, the number of 
patients admitted, the days of hospital care, and the water usage records for the main hospital 
wing that houses patients and here pharmaceuticals are excreted. Amounts of the active drugs 
excreted unchanged in urine and feces were based on published excretion rates taken from the 
pharmaceutical literature. Table 2 gives the usage pattern of 25 pharmaceutical compounds, 
expressed as predicted effluent concentration in the hospital wastewater. The predicted 
concentration is compared to compound’s estimated baseline toxicity towards green algae 
(Pseudokirchneriella subcapitata), which was calculated from Eqn. 8 
 –Log EC50 (Molar) = 0.95 log Dlipw(at pH = 7) + 1.53 (8) 
using the drug molecule’s water-to-lipid partition coefficient measured at an aqueous phase 
pH of 7. The “baseline” concentration would be the concentration of the pharmaceutical 
compound needed for the toxicity endpoint to be observed assuming a nonspecific narcosis 
mechanism. In the case of the green algae, the toxicity endpoint corresponds to the molar 
concentration of the tested drug substance at which the cell density, biomass, or O2 
production is 50 % of that of the untreated algae after a 72 to 96 hour exposure to the drug.  
The authors also reported predictive equations for estimating the baseline median lethal 
concentration for fish (Pimephales promelas, 96-hr endpoint)  
 –Log LC50 (Molar) = 0.81 log Dlipw(at pH = 7) + 1.65 (9) 
and the baseline effective concentration for mobility inhibition for water fleas (Daphnia 
magna, 48-hr. endpoint) 
 –Log EC50 (Molar) = 0.90 log Dlipw(at pH = 7) + 1.61 (10) 
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Pharmaceutical Compound PECHWW (Ǎg/L) PNECHWW (Ǎg/L) PEC versus PNEC 
    
Amiodarone 0.80 0.009 PEC Greater 
Clotrimazole 0.90 0.014 PEC Greater 
Trionavir 1.00 0.028 PEC Greater 
Progesterone 15.85 1.40 PEC Greater 
Meclozine 0.77 0.12 PEC Greater 
Atorvastatin 0.99 0.16 PEC Greater 
Isoflurane 94 29.8 PEC Greater 
Tribenoside 0.79 0.26 PEC Greater 
Ibuprofen 11.40 6.60 PEC Greater 
Clopidogrel 1.74 1.60 PEC Greater 
Amoxicillin 499 625 PEC Smaller 
Diclofenac 2.35 3.30 PEC Smaller 
Floxacillin 38.9 233 PEC Smaller 
Salicylic acid 17.2 134 PEC Smaller 
Paracetamol 64 583 PEC Smaller 
Thiopental 21 201 PEC Smaller 
Oxazepam 1.84 32 PEC Smaller 
Clarithromycin 5.41 122 PEC Smaller 
Rifampicin 0.59 16 PEC Smaller 
Tramadol 1.92 57 PEC Smaller 
Carbazmazepine 0.50 18 PEC Smaller 
Tetracaine 0.48 18 PEC Smaller 
Metoclopramide 3.27 136 PEC Smaller 
Prednisolone 2.10 139 PEC Smaller 
Erythomycin 1.40 132 PEC Smaller 
 
Table 2. Predicted Effluent Concentration of Pharmaceutical Compounds in the Wastewater 
of a General Hospital, PECHWW (in Ǎg/L) and the Predicted No Effect Concentration of the 
Pharmaceutical Compound to Green Algae, PNECHWW (in Ǎg/L) 
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Pharmaceutical Compound PECHWW (Ǎg/L) PNECHWW (Ǎg/L) PEC versus PNEC 
    
Ritonavir 0.86 0.03 PEC Greater 
Clotrimazole 0.39 0.01 PEC Greater 
Diclofenac 73.0 3.31 PEC Greater 
Mefanamic acid 5.38 0.78 PEC Greater 
Lopinavir 0.26 0.05 PEC Greater 
Nefinavir 0.71 0.16 PEC Greater 
Ibuprofen 26.3 6.62 PEC Greater 
Clorprothixen 2.53 0.91 PEC Greater 
Trimipramine 0.63 0.49 PEC Greater 
Meclozin 0.11 0.12 PEC Smaller 
Nevirapine 0.98 1.30 PEC Smaller 
Venlafaxine 24.6 35.5 PEC Smaller 
Promazine 1.67 2.70 PEC Smaller 
Olanazpine 8.41 14.9 PEC Smaller 
Levomepromazine 1.15 2.40 PEC Smaller 
Clopidogrel 0.72 1.60 PEC Smaller 
Methadone 3.75 10.5 PEC Smaller 
Carbamazepine 5.00 17.7 PEC Smaller 
Oxazepam 7.24 32.5 PEC Smaller 
Hexitidine 0.21 1.00 PEC Smaller 
Duloxetine 0.38 2.30 PEC Smaller 
Valproate 4.05 51 PEC Smaller 
Fluoxetine 0.54 6.90 PEC Smaller 
Lamotrigine 0.65 8.70 PEC Smaller 
Clozapine 0.97 16 PEC Smaller 
Diazepam 0.48 10 PEC Smaller 
Tramadol 2.60 57 PEC Smaller 
Pravastatin 3.39 77 PEC Smaller 
Amoxacillin 22.8 625 PEC Smaller 
Doxepin 0.17 4.90 PEC Smaller 
Citolopram  0.51 17 PEC Smaller 
Paracetamol 9.61 583 PEC Smaller 
Clomethiazole 0.28 23 PEC Smaller 
 
Table 3. Predicted Effluent Concentration of Pharmaceutical Compounds in the Wastewater 
of a Psychiatric Hospital, PECHWW (in Ǎg/L) and the Predicted No Effect Concentration of 
the Pharmaceutical Compound to Green Algae, PNECHWW (in Ǎg/L) 
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Most published baseline toxicity QSAR models were derived for neutral organic molecules 
and require the water-to-octanol partition coefficient, Ko/w as the input parameter. For 
compounds that can ionize, the water-to-octanol partition coefficient is an unsuitable 
measure of bioaccumulation and chemical uptake into biomembranes, the target site for 
baseline toxicants. Of the 10 of 25 pharmaceutical compounds listed in Table 2 have a 
predicted effluent concentration greater predicted no effect value, PNEC value. These 10 
compounds would be expected to exhibit toxicity towards the green algae if the algae where 
exposed to the hospital wastewater for 72 to 96 hours. The drug concentrations in the 
hospital wastewater would be significantly reduced once the effluent entered the general 
sewer system. Table 3 provides the predicted effluent concentration and calculated PNEC 
values of 33 pharmaceutical expected to be present in the wastewater from a psychiatric 
hospital. The pharmaceutical concentrations were based on hospital records of the 2,008 
patients who received 70,855 days of stationary care treatment. Many of the individuals who 
received treatment had acute psychiatric disorders that required strong medication. Nine of 
the 33 drugs listed have predicted effluent concentrations in excess of the PNEC value for 
green algae. Readers are reminded that the “baseline” concentration assumes a nonspecific 
narcosis mechanism, and that if the compound exhibits a reactive or other specific mode of 
toxic mechanism, the concentration would be much less.  
Since 1980, the U.S. Food and Drug Administration has required that environmental risk 
assessments be conducted on pharmaceutical compounds intended for human and 
veterinary use before the product can be marketed. Similar regulations were introduced by 
the European Union in 1997. The environmental impact tests are generally short-term 
studies that focus predominately on mortality as the toxicity endpoint for fish, daphnids, 
algae, plants, bacteria, earthworms, and select invertebrates (Khetan and Colins, 2007). 
There have been very few experimental studies directed towards determining the no effect 
concentration (NEC) of pharmaceutical compounds, and even fewer studies involving 
mixtures of pharmaceutical compounds. The limited experimental data available shows that 
the NEC is highly dependent upon animal and/or organism type, and on the specific 
endpoint being considered. For example, the NEC for ibuprofen for 21 day growth for 
freshwater gastropod (Planorbis carinatus) is 1.02 mg/L; the NEC for 21 day reproduction for 
Daphnia magna is less than 1.23 mg/L; the NEC for 30 day survival of Japanese medaka 
(Oryzias latipes) is 0.1 mg/L; the NEC for 90 day survival of Japanese medaka is 0.1 Ǎg/L. 
Mortality due to ibuprofen exposure was found to increase as the medaka fish matured 
(Han et al., 2010). More experimental NEC data is needed in order to properly perform 
environmental risk analyses. Until such data becomes available, one must rely on whatever 
acute toxicity data that one find and on in silico methods that allow one to predict missing 
experimental values from molecular structure considerations and from easy to measure 
physical properties.  
4. Abraham model: Prediction of environmental toxicity of pharmaceutical 
compounds 
Significant quantities of pharmaceutical drugs and personal healthcare products are 
discarded each year. The discarded chemicals find their way into the environment, and 
many end up in the natural waterways where they can have an adverse effect on marine life 
and other aquatic organisms. Standard test methods and experimental protocols have been 
established for determining the median mortality lethal concentration, LC50, for evaluating 
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the chronic toxicity, for determining decreased population growth, and for quantifying 
developmental toxicity at various life stages for several different aquatic organisms. 
Experimental determinations are often very expensive and time-consuming as several 
factors may need to be carefully controlled in order to adhere to the established, 
recommended experimental protocol. 
Aquatic toxicity data are available for relatively few organic, organometallic, and inorganic 
compounds. To address this concern, researchers have developed predictive methods as a 
means to estimate toxicities in the absence of experimental data. Derived correlations have 
shown varying degrees of success in their ability to predict the aquatic toxicity of different 
chemical compounds. In general, predictive methods are much better at estimating the 
aquatic toxicities of compounds that act through noncovalent or nonspecific modes of 
action. Nonpolar narcosis and polar narcosis are two such modes of nonspecific action. 
Nonpolar narcotic toxicity is often referred to as “baseline” or minimum toxicity. Polar 
narcotics exhibit effects similar to nonpolar narcotics; however, their observed toxicities are 
slightly more than “baseline” toxicity. Most industrial organic compounds have either a 
nonpolar or polar narcotic mode of action, which lacks covalent interactions between toxicant 
and organism. Predictive methods are generally less successful in predicting the toxicity of 
compounds whose action mechanism involves electro(nucleo)philic covalent reactivity or 
receptor-mediated functional toxicity. An example of a reactive toxicity mechanism would be 
alkane isothiocyanates that act as Michael-type acceptors, and undergo N-hydro-C-mercapto 
addition to cellular thiol functional groups (Schultz et al., 2008).  
The Abraham general solvation parameter model has proofed quite successful in predicting 
the toxicity of organic compounds to various aquatic organisms. Hoover and coworkers 
(Hoover et al., 2005) published Abraham model correlations for describing the nonspecific 
aquatic toxicity of organic compounds to: 
Fathead minnow: 
 
–log LC50 (Molar, 96 hr) = 0.996 + 0.418 E – 0.182 S + 0.417 A – 3.574 B + 3.377 V 
                (N= 196, SD = 0.276, R2 = 0.953, F = 779.4) 
(11)
 
Guppy: 
 
–log LC50 (Molar, 96 hr) = 0.811 + 0.782 E – 0.230 S + 0.341 A – 3.050 B + 3.250 V  
                (N= 148, SD = 0.280, R2 = 0.946, F = 493.1) 
(12)
 
Bluegill: 
 
–log LC50 (Molar, 96 hr) = 0.903 + 0.583 E – 0.127 S + 1.238 A – 3.918 B + 3.306 V  
                (N= 66, SD = 0.272, R2 = 0.968, F = 359.8) 
(13)
 
Goldfish: 
 
–log LC50 (Molar, 96 hr) = 0.922 – 0.653 E + 1.872 S + –0.329 A – 4.516 B + 3.078 V  
                (N= 51, SD = 0.277, R2 = 0.966, F = 253.7) 
(14)
 
Golden orfe: 
 
–log LC50 (Molar, 96 hr) = –0.137 + 0.931 E + 0.379 S + 0.951 A – 2.392 B + 3.244 V  
                (N= 49, SD = 0.269, R2 = 0.935, F = 127.0) 
(15)
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and Medaka high-eyes: 
 
–log LC50 (Molar, 96 hr) = –0.176 + 1.046 E + 0.272 S + 0.931 A – 2.178 B + 3.155 V  
                (N= 44, SD = 0.277, R2 = 0.960, F = 181.8) 
(16)
 
–log LC50 (Molar, 48 hr) = 0.834 + 1.047 E – 0.380 S + 0.806 A – 2.182 B + 2.667 V  
                (N= 50, SD = 0.292, R2 = 0.938, F = 132.8) 
(17)
 
The Abraham model described the median lethal toxicity (LC50) to within an average 
standard deviation of SD = 0.279 log units. The derived correlations pertain to chemicals 
that exhibit a narcosis mode-of-toxic action, and can be used to estimate the baseline toxicity 
of reactive compounds and to identify compounds whose mode-of-toxic action is something 
other than nonpolar and/or polar narcosis. For example, in the case of the fathead minnow 
database, Hoover et al. (2005) noted that 1,3-dinitrobenzene, 1,4-dinitrobenzene, 2-
chlorophenol, resorcinol, catechol, 2-methylimidazole, pyridine, 2-chloroaniline, acrolein 
and caffeine were outliers, suggesting that their mode of action involved some type of 
chemical specific toxicity. These observations are in accord with the earlier observations of 
Ramos et al. (1998) and Gunatilleka and Poole (1999). 
In a follow-up study (Hoover et al., 2007) the authors reported Abraham model expressions 
for correlating the median effective concentration for immobility of organic compounds to 
three species of water fleas: 
Daphnia magna: 
 
–log LC50 (Molar, 24 hr) = 0.915 + 0.354 E + 0.171 S + 0.420 A – 3.935 B + 3.521 V  
                (N= 107, SD = 0.274, R2 = 0.953, F = 410.0) 
(18)
 
–log LC50 (Molar, 48 hr) = 0.841 + 0.528 E – 0.025 S + 0.219 A – 3.703 B + 3.591 V  
                (N= 97, SD = 0.289, R2 = 0.964, F = 475.4) 
(19)
 
Ceriodaphnia dubia: 
 
–log LC50 (Molar, 24 hr & 48 hr combined) = 2.234 + 0.373 E – 0.040 S – 0.437 A –  
- 3.276 B + 2.763 V 
               (N= 44, SD = 0.253, R2 = 0.936, F = 111.0) 
(20)
 
Daphnia pulex: 
 
–log LC50 (Molar, 24 hr & 48 hr combined) = 0.502 + 0.396 E + 0.309 S + 0.542 A – 
- 3.457 B + 3.527 V 
                (N= 45, SD = 0.311, R2 = 0.962, F = 233.2) 
(21)
 
The data sets used in deriving Eqns. 18 – 21 included experimental log EC50 values for water 
flea immobility and for water flea death. The two toxicity endpoints were taken to be 
equivalent. Insufficient experimental details were given in many of the referenced papers 
for Hoover et al. to decide whether the water fleas were truly dead, or whether they were 
severely immobilized but still barely alive. Often, individual authors have reported the 
numerical value as a median immobilization effective concentration at the time of 
measurement, and in a later paper, the same authors referred to the same measured value as 
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the median lethal molar concentration, and vice versa. Von der Ohe et al. (2005) made 
similar observations regarding the published toxicity data for water fleas in their statement 
“.... some studies use mortality (LC50) and immobilization (EC50, effective concentration 
50%) as identical endpoints in the context of daphnid toxicity”. Von der Ohe et al. made no 
attempt to distinguish between the two. For notational purposes, we have denoted the 
experimental toxicity data for water fleas as –log LC50 in the chapter. We think that this 
notation is consistent with how research groups in most countries are interpreting the 
endpoint.  
Organic compounds used in deriving the fore-mentioned water flea correlations were for 
the most common industrial organic solvents. Hoover et al. (2007) did find published 
toxicity data for six antibiotics to both Daphnia magna and Ceriodaphnia dubia (Isidori et al. 
2005). Solute descriptors are available for three of the six compounds. One of the 
compounds, ofloxacin, has a carboxylic acid functional group, and would not be expected to 
fall on the toxicity correlation for nonpolar–polar narcotic compounds to daphnids. Solute 
descriptors for the remaining two compounds, erythromycin (E = 1.97, S = 3.55, A = 1.02, B 
= 4.71, and V = 5.77) and clarithromycin (E = 2.72, S = 3.65, A = 1.00, B = 4.98, and V = 
5.914), differ considerably from the the compounds used in deriving Eqns. 18-21. There was 
no obvious structural reason for the authors to exclude erythromycin and clarithromycin 
from the database; however, except that they did not want the calculated equation 
coefficients to be influenced by two compounds so much larger than the other compounds 
in the database and the calculated solute descriptors for both antibiotics were based on very 
limited number of experimental observations. Inclusion of erythromycin (–log LC50 = 4.51 
for Daphnia magna and –log LC50 = 4.86 for Ceriodaphnia dubia) and clarithromycin (–logLC50 
= 4.60 for Ceriodaphnia dubia and –log LC50 = 4.46 for Daphnia magna) in the regression 
analyses yielded: 
Daphnia magna: 
 
–log LC50 (Molar, 24 hr) = 0.896 + 0.597 E – 0.089 S + 0.462 A – 3.757 B + 3.460 V  (22)
 
Ceriodaphnia dubia: 
 
–log LC50 (Molar, 24 hr) = 1.983 + 0.373 E + 0.077 S – 0.576 A – 3.076 B + 2.918 V  (23)
 
Both correlations are quite good. The one additional compound had little effect on the 
statistics, SD = 0.253 (data set B correlation in Hoover et al., 2007) versus SD = 0.253 for 
Daphnia magna and SD = 0.256 versus SD = 0.253 for Ceriodaphnia dubia. Abraham model 
correlations have also been developed for estimating the baseline toxicity of organic 
compounds to Tetrahymena pyriformis (Hoover et al., 2007), Spirostomum ambiguum (Hoover et 
al., 2007), Psuedomonas putida (Hoover et al., 2007), Vibrio fischeri (Gunatilleka and Poole, 
1999) and several tadpole species (Bowen et al., 2006). 
5. Methods to remove pharmaceutical products from the environment 
The fate and effect of pharmaceutical drugs and healthcare products is not easy to predict. 
Medical compounds may be for human consumption to combat diseases or treat illnesses, or 
to relive pain and reduce inflammation. Many anti-inflammatory and analgesic drugs are 
available commercially without prescription as over-the-counter medications, with an 
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estimated annual consumption of several hundred tons in developed countries. 
Pharmaceutical products are also used as veterinary medicines to treat illnesses, to promote 
livestock growth, to increase milk production, to manage reproduction, and to prevent the 
outbreak of diseases or parasites in densely populated fish farms. Antibiotics and 
antimicrobials are used to control and prevent diseases caused by microorganisms. 
Antiparasitic and anthelmintic drugs are approved for the treatment and control of internal 
and external parasites. The pharmaceutical compounds find their way into the environment by 
many exposure pathways, human/animal urine and feces excretion, discharge and runoff 
from fish farms, as shown in Figure 2. Once in the environment, the drugs and their 
degradation metabolites are adsorbed onto the soil and dissolved into the natural waterways. 
 
 
Fig. 2. Environmental occurrence and fate of pharmaceutical compounds used in human 
treatments and veterinary applications. 
Published studies have reported the environmental damage that human and veterinary 
compounds have on aquatic organisms and microorganisms, on birds and on other forms of 
wildlife. For example, diclofenac (drug commonly used in ambulatory care) inhibits the 
microorganisms that comprise lotic river biofilms at a drug concentration level around 100 
Ǎg/L (Paje et al., 2002), and damages the kidney and liver cell functions of rainbow trout at 
concentration levels of 1 Ǎg/L (Triebskorn, et al., 2004). Diclofenac affects nonaquatic 
organisms as well. India, Pakisan and Nepal banned the manufacture of veterinary 
formulations of diclofenac to halt the decline of three vulture species that were being 
poisoned by the diclofenac residues present in domestic livestock carcasses (Taggart et al., 
2009). The birds died from kidney failure after eating the diclofenac-tained carcasses. 
Concerns have also been expressed about the safety of ketoprofen. Naidoo and coworkers 
(2010a,b) reported vulture mortalities at ketoprofen dosages of 1.5 and 5 mg/kg vulture 
body weight, which is within the level for cattle treatment. Residues of two fluorquinolone 
veterinary compounds (enrofloxacin and ciprofloxacin), found in unhatched eggs of giffon 
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vultures (Gyps fulvus) and red kites (Milvus milvus), are thought to be responsible for the 
observed severe alterations of embryo cartilage and bones, that prevented normal embryo 
development and successful egg hatching (Lemus et al., 2009). 
Removal of pharmaceutical residues and metabolites in municipal wastewater treatment 
facilities is a major challenge in reducing the discharge of these chemicals into the 
environment. Many wastewater facilities use an “activated sludge process” that involves 
treating the wastewater with air and a biological floc composed of bacteria and protozoans 
to reduce the organic content. Treatment efficiency for removal of analgesic and anti-
inflammatory drugs varies from “very poor” to “complete breakdown” (Kulik et al., 2008), 
and depends on seasonal conditions, pH, hydraulic retention time and sludge age (Tauxe-
Wuersch et al., 2005; Nikolaou et al., 2005).  
Advanced treatment processes, in combination with the activated sludge process, results in 
greater pharmaceutical compound removal from wastewater. Advanced processes that have 
been applied to the effluent from the activated sludge treatment include sand filtration, 
ozonation, UV irridation and activated carbon adsorption. Of the fore-mentioned processes, 
ozonation was found to be the most effective for complete removal for most analgesic and 
anti-inflammatory drugs. Ozone reactivity depends of the functional groups present in the 
drug molecule, as well as the reaction conditions. For example, the presence of a carboxylic 
functional group on an aromatic ring reduces ozone reaction with the aromatic ring carbons. 
Carboxylic groups are electron withdrawing. Electron-donating substituents, such as –OH 
groups, facilitate the attack of ozone to aromatic rings. Not all pharmaceutical compounds 
are reactive with ozone. For such compounds, it may be advantageous to perform the 
ozonation under alkaline conditions, where hydroxyl radicals are readily abundant. 
Hydroxyl radicals are highly reactive with a wide range of organic compounds, converting 
the compound to simplier and less harmful intermediates. With sufficient reaction time and 
appropriate reaction conditions, hydroxyl radicals can convert organic carbon to CO2. 
Several methods have been successfully employed to generate hydroxyl radicals. Fenton 
oxidation is an effective treatment for removal of pharmaceutical compounds and other 
organic contaminants from wastewater samples. The process is based on 
 Fe2+ + H2O2 ------> Fe3+ + OH– + OH· (24) 
the production of hydroxyl radicals from Fenton’s reagent (Fe2+/H2O2) under acidic 
conditions, with Fe2+ acting as a homogeneous catalyst. Once formed, hydroxyl radicals can 
oxidize organic matter (i.e. organic pollutants) with kinetic constants in the 107 to 1010 M–1 s–1 at 
20 oC (Edwards et al., 1992; Huang et al., 1993). Fenton’s technique has been used both as a 
wastewater pretreatment prior to the activated sludge process and as a post-treatment method 
after the activated sludge process. A full-scale pharmaceutical wastewater treatment facility 
using the Fenton process as the primary treatment method, followed by a sequence of 
activated sludge processes as the secondary treatment method, has been reported to provide 
an overall chemical oxygen demand removal efficiency of up to 98 % (Tekin et al., 2006). 
UV/H2O2 is an effective treatment for removal of pharmaceutical compounds and other 
organic contaminants from wastewater samples. The effluent is subjected to UV radiation. 
Some of the dissolved organic will absorb UV light directly, resulting in the destruction of 
chemical bonds and subsequent breakdown of the organic compound. Hydrogen peroxide 
is added to treat those compounds that do not degrade quickly or efficiently by direct UV 
photolysis. Hydrogen peroxide undergoes photolytic cleavage to OH radicals 
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 H2O2 + hǎ ------> 2 OḢ̇· (25) 
at a stoichiometric ratio of 1:2, provided that the radiation source has sufficient emission at 
190 – 200 nm. Disadvantages of the advanced oxidation processes are the high operating 
costs that are associated with: (a) high electricity demand (ozone and UV/H2O2); (b) the 
relatively large quantities of oxidants and/or catalysts consumed (ozone, hydrogen 
peroxide, and iron salts); and (c) maintaining the required pH range (Fenton process). 
 
 
Fig. 3. Basic photocatalyic process involving TiO2 particle 
Photo-catalytic processes involving TiO2 and/or TiO2 nanoparticles have also been 
successful in removing pharmaceutical compounds pharmaceutical compounds (PC) from 
aqueous solutions. The basic process of photocatalysis consists of ejecting an electron from 
the valence band (VB) to the conduction band (CB) of the TiO2 semiconductor  
 TiO2 + hǎ → ecb− + hvb+ (26) 
creating an h+ hole in the valence band. This is due to UV irradiation of TiO2 particles with 
an energy equal to or greater than the band gap (hǎ > 3.2 eV). The electron and hole may 
recombine, or may result in the formation of extremely reactive species (like OH and O2−*) 
at the semi-conductor surface 
 hvb+ + H2O → ·OH + H+  (27) 
 hvb+ + OH− → ·OHads  (28) 
 ecb− + O2 → O2*− (29) 
as depicted in Figure 3, and/or a direct oxidation of the dissolved pharmaceutical 
compound (PC) 
 hvb+ + PCads → PC+ads  (30) 
The O2−* that is produced in reaction scheme 35 undergoes further reactions to form 
 O2−* + H+ → HO2·  (31) 
 H+ + O2−* + HO2· → H2O2 + O2 (32) 
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 H2O2 + hǎ → 2 ·OH (33) 
additional hydroxyl radicals that subsequently react with the dissolved pharmaceutical 
compounds (Gad-Allah et al., 2011). Titanium dioxide is used in the photo-catalytic 
processes because of its commercial availability and low cost, relatively high photo-catalytic 
activity, chemical stability resistance to photocorrosion, low toxicity and favorable wide 
band-gap energy. 
Published studies have shown that sonochemical degradation of pharmaceutical and 
pesticide compounds can be effective for environmental remediation. Sonolytic degradation 
of pollutants occurs as a result of the continuous formation and collapse of cavitation 
bubbles on a microsecond time scale. Bubble collapse leads to the formation of a hot 
nucleus, characterized with extremely high temperatures (thousands of degrees) and 
pressure (hundreds of atmospheres). 
6. Abraham model: Prediction of sensory and biological responses 
Drug delivery to the target is an important consideration in drug discovery. The drug must 
reach the target site in order for the desired therapeutic effect to be achieved. Inhaled 
aerosols offer significant potential for non-invasive systemic administration of therapeutics 
but also for direct drug delivery into the diseased lung. Drugs for pulmonary inhalation are 
typically formulated as solutions, suspensions or dry powders. Aqueous solutions of drugs 
are common for inhalational therapy (Patton and Byron, 2007). Yet, about 40% of new active 
substances exhibit low solubility in water, and many fail to become marketed products due 
to formulation problems related to their high lipophilicity (Tang et al., 2008; Gursoy and 
Benita, 2004). Formulations for drug delivery to the respiratory system include a wide 
variety of excipients to assist aerosolisation, solubilise the drug, support drug stability, 
prevent bacterial contamination or act as a solvent (Shaw, 1999; Forbes et al., 2000). Organic 
solvents that are used or have been suggested as propellents for inhalation drug delivery 
systems include semifluorinated alkanes (Tsagogiorgas et al., 2010), binary ethanol-
hydrofluoroalkane mixtures (Hoye and Myrdal, 2008), fluorotrichloromethane, 
dichlorodifluoromethane and 1,2-dichloro-1,1,2,2-tetrafluoroethane (Smyth 2003).  
Eye irritation thresholds (EIT), nasal irritation (pungency) thresholds (NPT), and odor 
detection thresholds (ODT) are related in that together they provide a warning system for 
unpleasant, noxious and dangerous chemicals or mixtures of chemicals. ODT values should 
not be confused with odor recognition. The latter area of research was revolutionized by the 
discovery of the role of odor receptors by Buck and Axel (Nobel Prize in physiology and 
medicine, 2004). It is now known that there are some 400 different active odor receptors in 
humans, that a given odor receptor can interact with a number of different chemicals, and 
that a given chemical can interact with several different odor receptors (Veithen et al., 2009; 
Veithen et al., 2010). This leads to an almost infinite matrix of interactions, and is a major 
reason why any connection between molecular structure and odor recognition is limited to 
rather small groups of chemicals (Sell, 2006). However, the first indication of an odor is 
given by the detection threshold; only at appreciably higher concentrations of the odorant 
can it be recognized. Another vital difference between odor detection and odor recognition 
is that ODT values can be put on a rigorous quantitative scale (Cometto-Muňiz, 2001), 
whereas odor recognition is qualitative and subject to leaning and memory (Wilson and 
Stevenson, 2006). As we shall see, it is possible, with some limitations, to obtain equations 
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that connect ODT values with chemical structure in a way that is impossible for odor 
recognition. 
A ‘back-up’ warning system is provided through nasal irritation (pungency) thresholds, 
where NPT values are about 103 larger than ODT. Nasal pungency occurs through 
activation of the trigeminal nerve, and so has a different origin to odor itself. Because 
chemicals that illicit nasal irritation will generally also provoke a response with regard to 
odor detection, it is not easy to determine NPT values without interference from odor. 
Cometto-Muňiz and Cain used subjects with no sense of smell, anosmics, in order to obtain 
NPT values through a rigorous systematic method; a detailed review is available (Cometto-
Muňiz et al., 2010). Cometto-Muňiz and Cain also devised a similar rigorous systematic 
method to obtain eye irritation thresholds (Cometto-Muňiz, 2001). Values of EIT are very 
close to NPT values. Eye irritation and nasal irritation (or pungency) are together known as 
sensory irritation. In addition to these human studies, a great deal of work has been carried 
out on upper respiratory tract irritation in mice. A quantitative scale was devised by Alarie 
(Alarie, 1966, 1973, 1981, 1988) and developed into a procedure for establishing acceptable 
exposure limits to airborne chemicals. 
Before applying any particular equation to biological activity of VOCs, it is useful to 
consider various possible models (Abraham, et al., 1994). A number of models were 
examined; the ‘two-stage’ model shown in Figure 4 gave a good fit to experimental data, 
whilst still allowing for unusual or ‘outlying’ effects. In stage 1, the VOC is transferred from 
the gas phase to a receptor phase. This transfer will resemble the transfer of chemicals from 
the gas phase to solvents that have similar chemical properties to the receptor phase. In 
particular there will be ‘selectivity’ between VOCs in accordance with their chemical 
properties and the chemical properties of the receptor phase. In stage 2, the VOC activates 
the receptor. If this is simply an on-off process, so that all VOCs activate the receptor 
similarly, then the resultant biological activity will correspond to the selectivity of the VOCs 
in the first stage, and can then be represented by some structure-activity correlation. 
However, if some of the VOCs activate the receptor through ‘specific’ effects, they will 
appear as outliers to any structure-property correlation. Indeed, if the majority of VOCs act 
through specific effects, then no reasonable structure-activity correlation will be obtained. 
 
Gas phase
Receptor phase
R1
2
VOC
 
Fig. 4. A two-stage mechanism for the biological activity of gases and vapors; R denotes the 
receptor.  
A stratagem for the analysis of biological activity of VOCs in a given process is therefore to 
construct some quantitative structure-activity equation that resembles similar equations for 
the transfer of VOCs from the gas phase to solvents. If the obtained equation is statistically 
and chemically reasonable, then it may be deduced that stage 1 is the main step. If a 
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reasonable equation is obtained, but with a number of outliers, then stage 1 is probably the 
main step for most VOCs, but stage 2 is important for the VOCs that are outliers. If no QSAR 
can be set up, then stage 2 will be the main step for most VOCs. The linear free energy 
relationship or LFER, Eqn. 3, has been applied to transfers of compounds from the gas phase 
to a very large number of solvents (Abraham et al., 2010a), and so is well suited as a general 
equation for the analysis of biological activity of VOCs.  
Early work on attempts to correlate ODT values with various VOC properties has been 
summarized (Abraham, 1996). The first general application of Eqn. 3 to ODT values yielded 
Eqn. 34 (Abraham et al., 2001; 2002). Note that (1/ODT) is used so that as log (1/ODT) 
becomes larger, the VOC becomes more potent, and that the units of ODT are ppm. There 
were a considerable number of outliers, including carboxylic acids, aldehydes, propanone, 
octan-1-ol, methyl acetate and t-butyl alcohol, suggesting that for many of the VOCs studied 
stage 2 in Figure 4 is important.  
 
 Log (1/ODT) = -5.154 + 0.533 · E + 1.912 · S + 1.276 · A + 1.559 · B + 0.699 ·L 
                          (N= 50, SD = 0.579, R2 = 0.773, F = 28.7) 
(34)
 
Aldehydes and carboxylic acids could be included in the correlation through an indicator 
variable, H, that takes the value H = 2.0 for aldehydes and carboxylic acids and H = 0 for all 
other VOCs. The correlation could also be improved slightly by use of a parabolic 
expression in L, leading to Eqn. 35 (Abraham et al., 2001; 2002). 
 
Log (1/ODT) = -7.720 - 0.060 · E + 2.080 · S + 2.829 · A + 1.139 · B + 
 +2.028 · L - 0.148 · L2 + 1.000· H  
                         (N= 60, SD = 0.598, R2 = 0.850, F = 44.0) 
(35)
 
Although Eqn 35 is more general than Eqn 34, it suffers in that it cannot be compared to 
equations for other processes obtained through the standard Eqn 3. Coefficients for 
equations that correlate the transfer of compounds from the gas phase to solvents as log K, 
the gas-solvent partition coefficient, are given in Table 4 (Abraham et al., 2010a). The most 
important coefficients are the s-coefficient that refers to the solvent dipolarity, the a-
coefficient that refers to the solvent hydrogen bond basicity, the b-coefficient that refers to 
the solvent hydrogen bond basicity, and the l-coefficient that is a measure of the solvent 
hydrophobicity. For a solvent to be a model for stage 1 in the two-stage mechanism, we 
expect it to exhibit both hydrogen bond acidity and hydrogen bond basicity, since the 
peptide components of a receptor will include the –CO-NH- entity. In Table 4 we give 
details of solvents mainly with significant b- and a-coefficients. There is only a rather poor 
connection between the coefficients in Eqn. 42 and those for the secondary amide solvents in 
Table 4, suggesting, once again, that for odor thresholds stage 2 must be quite important.  
The importance of stage 2 is illustrated by the observations of a ‘cut-off’ effect in odor 
detection thresholds (Cometto-Muňiz and Abraham, 2009a, 2009b, 2010a, 2010b). On 
ascending a homologous series of chemicals, ODT values decrease regularly with increase in 
the number of carbon atoms in the compounds. That is, the chemicals become more potent. 
However, a point is reached at which there is no further decrease in ODT or, even, ODTs 
begin to rebound and increase with increase in carbon chain length (Cometto-Muňiz and 
Abraham, 2009a, 2010a). This outcome could possibly be due to a size effect. A point is 
reached at which the VOC becomes too large and the increase in potency, reflected in 
decreasing ODTs is halted as just described. 
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Solvent c E s a b l 
Methanol -0.039 -0.338 1.317 3.826 1.396 0.773 
Ethanol 0.017 -0.232 0.867 3.894 1.192 0.846 
Propan-1-ol -0.042 -0.246 0.749 3.888 1.076 0.874 
Butan-1-ol -0.004 -0.285 0.768 3.705 0.879 0.890 
Pentan-1-ol -0.002 -0.161 0.535 3.778 0.960 0.900 
Hexan-1-ol -0.014 -0.205 0.583 3.621 0.891 0.913 
Heptan-1-ol -0.056 -0.216 0.554 3.596 0.803 0.933 
Octan-1-ol -0.147 -0.214 0.561 3.507 0.749 0.943 
Octan-1-ol (wet) -0.198 0.002 0.709 3.519 1.429 0.858 
Ethylene glycol -0.887 0.132 1.657 4.457 2.355 0.565 
Water -1.271 0.822 2.743 3.904 4.814 -0.213 
N-Methylformamide -0.249 -0.142 1.661 4.147 0.817 0.739 
N-Ethylformamide -0.220 -0.302 1.743 4.498 0.480 0.824 
N-Methylacetamide -0.197 -0.175 1.608 4.867 0.375 0.837 
N-Ethylacetamide -0.018 -0.157 1.352 4.588 0.357 0.824 
Formamide -0.800 0.310 2.292 4.130 1.933 0.442 
    
Diethylether 0.288 -0.347 0.775 2.985 0.000 0.973 
Ethyl acetate 0.182 -0.352 1.316 2.891 0.000 0.916 
Propanone 0.127 -0.387 1.733 3.060 0.000 0.866 
Dimethylformamide -0.391 -0.869 2.107 3.774 0.000 1.011 
N-Formylmorpholine -0.437 0.024 2.631 4.318 0.000 0.712 
DMSO -0.556 -0.223 2.903 5.037 0.000 0.719 
Table 4. Coefficients in Eqn. 3 for Partition of Compounds from the Gas Phase to dry 
Solvents, at 298 K  
As regards nasal pungency thresholds, a very detailed review is available on the anatomy 
and physiology of the human upper respiratory tract, the methods that have been used to 
assess irritation, and the early work on attempts to devise equations that could correlate 
nasal pungency thresholds (Doty et al., 2004). The first application of Eqn 3 to nasal 
pungency thresholds used a variety of chemicals including aldehydes and carboxylic acids 
(Abraham et al., 1998c). Later on, NPT values for several terpenes were included (Abraham 
et al., 2001) to yield Eqn. 36 (Abraham et al., 2010b) with NPT in ppm; of all the chemicals 
tested, only acetic acid was an outlier. Note that the term s· S was statistically not significant 
and was excluded. Unlike ODT, it seems as though for the compounds studied, stage 1 in 
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the two-stage mechanism is the only important step. This is reflected in that there are 
several solvents in Table 4 with coefficients quite close to those in Eqn. 36; N-
methylformamide is one such solvent, and would be a reasonable model for solubility in a 
matrix containing a secondary peptide entity.  
 
Log (1/NPT) = -7.700 + 1.543 · S + 3.296 · A + 0.876 · B + 0.816 · L 
                         (N = 47, SD = 0.312, R2 = 0.901, F = 45.0) 
(36)
 
Along a homologous series of VOCs, the only descriptor in Eqn. 36 that changes 
significantly is L. Since L increases regularly along a homologous series, then log 1/(1/NPT) 
will increase regularly – that is the VOC will become more potent. A very important finding 
(Cometto-Muňiz et al., 2005a) is that this regular increase does not continue indefinitely. For 
example, along the series of alkyl acetates log (1/NPT) increases up to octyl acetate, but 
decyl acetate cannot be detected. This is not due to decyl acetate having too low a vapor 
pressure to be detected, but is a biological ‘cut-off’ effect. One possibility (Cometto-Muňiz et 
al., 2005a) is that for homologous series, the cut-off point is reached when the VOC is too 
large to activate the receptor. The effect of the cut-off point is shown in Figure 5 where log 
(1/NPT) is plotted against the number of carbon atoms in the n-alkyl group for n-alkyl 
acetates. A similar situation is obtained for the series of carboxylic acids, where the irritation 
potency increases as far as octanoic acid which now exhibits the cut-off effect. However, the 
compounds phenethyl alcohol, vanillin and coumarin also failed to provoke nasal irritation 
which suggests that stage 1 in the two-stage process is not always the limiting step. Two 
other equations for NPT have been reported (Famini et al., 2002; Luan et al., 2010) but the 
equations contain fewer compounds than Eqn. 36 and neither of them have improved 
statistics.  
 
 
Fig. 5. A plot of log (1/NPT) for n-alkyl acetates against N, the number of carbon atoms in 
the n-alkyl group; ● observed values, ฀ calculated values from Eqn 36. 
A related property to eye irritation in humans is the Draize rabbit eye irritation test (Draize 
et al., 1944). A given substance is applied to the eye of a living rabbit, and the effects of the 
substance on various parts of the eye are graded and used to derive an eye irritation score. 
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All kinds of substances have been applied, including soaps, detergents, aqueous solutions of 
acids and bases, and various solids. The test is so distressing to the animal that it has largely 
been phased out, but Draize scores of chemicals as the pure liquid are of value and were 
used to develop a quantitative structure-activity relationship (Abraham et al., 1998a). It was 
reasoned that if Draize scores of the pure liquids, DES, were mainly due to a transport 
mechanism, for example step 1 in Figure 4, then they could be converted into an effect for 
the corresponding vapors through DES / Po = K. Here K is a gas to solvent phase 
equilibrium or partition coefficient, Po is the saturated vapor pressure of the pure liquid in 
ppm at 298 K, and DES/ Po is equivalent to the solubility of a gaseous VOC in the 
appropriate receptor phase. 
Values of DES for 38 liquids were converted into DES/ Po and the latter regressed against 
the Abraham descriptors. The point for propylene carbonate was excluded and for the 
remaining 37 compounds Eqn. 37 was obtained; the term in e· E was not significant and was 
excluded. The coefficients in Eqn. 37 quite resemble those for solubility in N-
methylformamide, Table 4, and this suggests that the assumption of a mainly transport 
mechanism is reasonable.  
 
Log (DES / Po) = -6.955 + 1.046 · S + 4.437 · A + 1.350 · B + 0.754 · L  
                            (N = 37, SD = 0.320, R2 = 0.951, F = 155.9) 
(37)
 
At that time, values of EIT for only 17 compounds were available, and so an attempt was 
made to combine the modified Draize scores with EIT values in order to obtain an equation 
that could be used to predict EIT values in humans (Abraham et al.,1998b). It was found that 
a small adjustment to DES / Po values by 0.66 was needed in order to combine the two sets 
of data as in Eqn. 38; SP is either (DES / Po - 0.66 or EIT). EIT is in units of ppm. 
 
Log (SP) = -7.943 + 1.017 · S + 3.685 · A + 1.713 · B + 0.838 · L 
                 (N = 54, SD = 0.338, R2 = 0.924, F = 149.69)   
(38)
 
A slightly different procedure was later used to combine DES / Po values for 68 compounds 
and 23 EIT values (the nomenclature MMAS was used instead of DES). For all 91 
compounds, Eqn. 39 was obtained. Instead of the adjustment of -0.66 to DES / Po, an 
indicator variable, I, was used; this takes the value I = 0 for the EIT compounds, and I = 1 
for the Draize compounds (Abraham et al., 2003).  
 
Log (SP) = -7.892 - 0.397 · E + 1.827 · S + 3.776 · A + 1.169 · B + 0.785 · L + 0.568 · I 
                (N = 91, SD = 0.433, R2 = 0.936, F = 204.5) 
(39)
  
The eye irritation thresholds in humans, based on a standardized systematic protocol, were 
those determined over a number of years (Cometto-Muňiz & Cain, 1991, 1995, 1998; 
Cometto-Muňiz et al., 1997, 1998a, 1998b).  
Later work (Cometto-Muňiz  et al., 2005b, 2006, 2007a, 2007b; Cometto-Muňiz and Abraham, 
2008) revealed the existence of a cut-off point in EIT on ascending a number of homologous 
series. Just as with NPT, these cut-off points are not due to the low vapor pressure of higher 
members of the homologous series, but appear to relate to a lack of activation of the 
receptor. If this is due to the size of the VOC, then the overall length may be the determining 
factor, because on ascending a homologous series, both the width and depth of the 
homologs remain constant. It is interesting that odorant molecular length has been 
suggested as one factor in the olfactory code (Johnson and Leon, 2000). Whatever the cause 
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of the cut-off point, it renders all equations for the correlation and prediction of EIT subject 
to a size restriction.  
The only animal assay concerning VOCs is the very important ‘mouse assay’ first 
introduced by Alarie (Alarie, 1966, 1973, 1981, 1998; Alarie et al., 1980), and developed into a 
standard test procedure for the estimation of sensory irritation (ASTM, 1984). In the assay, 
male Swiss-Webster mice are exposed to various vapor concentrations of a VOC and the 
concentration at which the respiratory rate is reduced by 50% is taken as the end-point and 
denoted as RD50. An evaluation of the use RD50 to establish acceptable exposure levels of 
VOCs in humans has recently been published (Kuwabara et al., 2007) 
There were a number of attempts to relate RD50 values for a series of VOCs to physical 
properties of the VOCs such as the water-octanol partition coefficient, Poct) or the gas-
hexadecane partition coefficient, but these relationships were restricted to particular 
homologous series (Nielsen and Alarie, 1982; Nielsen and Bakbo, 1985; Nielsen and 
Yamagiwa, 1989; Nielsen et al., 1990). A useful connection was between RD50 and the VOC 
saturated vapor pressure at 310 K, viz: RD50 / VPo = constant (Nielsen and Alarie, 1982). 
This is known as Ferguson’s rule (Ferguson, 1939) and although it was claimed to have a 
rigorous thermodynamic basis (Brink and Posternak, 1948) it is now known to be only an 
empirical relationship (Abraham et al., 1994). 
RD50 values were also obtained using a different strain of mice, male Swiss OF1 mice (De 
Ceaurriz et al., 1981) and were used to obtain relationships between log (1/ RD50) and VOC 
properties such as log Poct, or boiling point for compounds that were classed as nonreactive 
(Muller and Gref, 1984; Roberts, 1986). The data used previously (Roberts, 1986) were later 
fitted to Eqn. 3 to yield Eqn 40 for unreactive compounds (Abraham et al., 1990)  
 
Log (1/FRD50) = -0.596 + 1.354 · S + 3.188 · A + 0.775 · L 
                          (N = 39, SD = 0.103, R2 = 0.980) 
(40)
 
FRD50 is in units of mmol m-3, rather than ppm, but this affects only the constant in Eqn 40. 
The fine review of Schaper lists RD50 values for not only Swiss-Webster mice but also for 
Swiss OF1 mice (Schaper, 1993), and an updated equation for Swiss OF1 mice in terms of 
RD50 was set out (Abraham, 1996). 
 
Log (1/RD50) = -6.71 + 1.30 · S + 2.88 · A + 0.76 · L 
                        (N = 45, SD = 0.140, R2 = 0.962, F = 350) 
(41)
 
The Schaper data base was used to test if log (1/RD50) values for nonreactive VOCs could be 
correlated with gas to solvent partition coefficients, as log K, and reasonable correlations were 
found for a number of solvents (Abraham et al., 1994; Alarie et al., 1995, 1996). In order to 
analyze values for a wide range of VOCs it was thought important to distinguish compounds 
that illicit an effect through a ‘chemical’ mechanism or through a ‘physical’ mechanism, these 
terms being equivalent to ‘reactive’ or ‘nonreactive’ (Alarie et al., 1998a). The Ferguson rule 
was used to discriminate between the two classes; if RD50 / VPo > 0.1 the VOC was deemed to 
act by a physical mechanism (p), and if RD50 / VPo < 0.1 the VOC was considered to act by a 
chemical mechanism (c). For 58 VOCs acting by a physical mechanism, Eqn 42 was obtained 
(Alarie et al., 1998b) for Swiss OF1 mice and Swiss-Webster mice. 
 
Log (1/RD50) = -7.049 + 1.437 · S + 2.316 · A + 0.774 · L 
                        (N = 58, SD = 0.354, R2 = 0.840, F = 94.5) 
(42)
www.intechopen.com
 
Toxicity and Drug Testing 284 
A more recent analysis has been carried out (Luan et al., 2006), using the previous data and 
division into physical and chemical mechanisms. For 47 VOCs acting by a physical 
mechanism, Eqn 43 was obtained. 
 
Log (1/RD50) = -5.550 + 0.043· Re + 6.329· RPCG + 0.377· ICave + 0.049·  
CHdonor – 3.826 ·RNSB + 0.047· ZX  
                        (N = 47, SD = 0.362, R2 = 0.844, F = 36.1) 
(43)
 
The statistics of Eqn 43 are not as good as those of Eqn 42, and since some of the descriptors 
in Eqn 43 are chemically almost impossible to interpret (ICave is the average information 
content and ZX is the ZX shadow) it has no advantage over Eqn 42. What is of more interest 
is that it was possible to derive an equation for VOCs acting by a chemical mechanism (Luan 
et al., 2006), 
 
Log (1/RD50) = 8.438 + 0.214· PPSA3 + 0.017· Hf – 22.510· Vcmax + 0.229· 
BIC + 44.508· (HDCA + 1/TMSA) + 0.049 ·BOminc 
                        (N = 67, SD = 0.626, R2 = 0.737, F = 28.0) 
(44)
 
Although, again, Eqn 44 is chemically difficult to interpret, it does show that it is possible to 
estimate RD50 values for VOCs that are reactive and act through a chemical mechanism.  
About 20 million patients receive a general anesthetic each year in the USA. In spite of 
considerable effort the specific site of action of anesthetics is still not well known. However, 
even if the actual site of action is not known, it is possible that a general mechanism on the 
lines shown in Figure 4 obtains. In the first stage the anesthetic is transported from the gas 
phase to a site of action, and in the second stage interaction takes place with a target 
receptor, a variety of which have been suggested ((Franks, 2006; Zhang et al., 2007; Steele et 
al., 2007). Then if stage 1 is a major component, we might expect that a QSAR could be 
constructed for inhalation anesthesia. It is noteworthy that a QSAR on the lines of Eqn. 2 
was constructed for aqueous anesthesia as long ago as 1991 (Abraham et al., 1991). Since 
then, rather little has been achieved in terms of inhalation anesthesia. The usual end point in 
inhalation anesthesia is the minimum alveolar concentration, MAC, of an inhaled anesthetic 
agent that prevents movement in 50 % of subjects in response to noxious stimulation. In rats, 
this is electrical or mechanical stimulation of the tail. MAC values are expressed in 
atmospheres, and correlations are carried out using log (1/MAC) so that the smaller is MAC 
the more potent is the anesthetic. It was shown (Sewell and Halsey, 1997) that shape similarity 
indices gave better fits for log (1/MAC) than did gas to olive oil partition coefficients, but the 
analysis was restricted to a model for 10 fluoroethanes for which R2 = 0.939 and a different 
model for 8 halogenated ethers for which R2 = 0.984 was found. A completely different model 
of inhalation anesthesia.has been put forward (Sewell and Sear, 2004, 2006) in which no 
consideration is taken as to how a gaseous solute is transported to a receptor, but solute-
receptor interactions are calculated. However, two different receptor models were needed, one 
for a particular set of nonhalogenated compounds and one for a particular set of halogenated 
compounds, so the generality of the model seems quite restricted. 
A QSAR for inhalation anesthesia was eventually obtained using the LFER, Eqn. 3, as 
follows (Abraham et al., 2008) 
 
Log (1/MAC) = - 0.752 - 0.034 · E + 1.559 · S + 3.594· A + 1.411 · B + 0.687 · L 
                          (N = 148, SD = 0.192, R2 = 0.985, F = 1856.1) 
(45)
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The only compounds not included in Eqn. 45 were 1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorohexane 
and 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoroheptan-1-ol which were known to be subject to cut-off 
effects, and 1-octanol where the observed MAC value was subject to a greater error than 
usual. Hence Eqn. 45 is a very general equation, and it can be suggested that stage 1 in 
Figure 4 does indeed represent the main process. 
A related biological end point to inhalation anesthesia is that of convulsant activity. It has 
been observed that a number of compounds expected to exhibit anesthesia actually provoke 
convulsions in rats (Eger et al., 1999). The end point, as for inhalation anesthesia, is taken as 
the compound vapor pressure in atm that just induces convulsion, CON. Eqn 3 was applied 
to the observed data yielding Eqn 46 (Abraham and Acree, 2009)  
 
Log (1/CON) = -0.573 -0.228 · E + 1.198 · S + 3.232 · A + 3.355 · B + 0.776 · L  
                         (N = 44, SD = 0.167, R2 = 0.978, F = 344.2) 
(46)
 
In terms of structural features it was shown that the anesthetics tended to have large 
hydrogen bond acidities whereas convulsants tended to have zero or small hydrogen bond 
acidities. The only other notable structural feature was that convulsants had larger values of 
L and anesthetics tended to have smaller values of L. Since L is somewhat related to size, the 
convulsants are generally larger than the inhalation anesthetics.  
 
 
Fig. 6. Plots of VOC activity, Y, against VOC carbon number, N, illustrating the use of an 
indicator variable, I.  
It was pointed out (Abraham et al., 2010c) that a large number of equations on the lines of 
Eqn. 3 for various biological and toxicological effects of VOCs had been constructed, these 
equations mainly representing stage 1 in Figure 4. Since this stage refers to the transfer of a 
VOC from the gas phase to some biological phase, it was argued that it might be possible to 
amalgamate all these equations into one general equation for the biological and toxicological 
activity of VOCs. Consider plots of toxicological activity, Y, against the number of carbon 
atoms, N, in a homologous series of VOCs. If the two lines are parallel, then a simple 
indicator variable, I, could be used to bring then both on the same line, as shown in Figure 6. 
If the two lines are not parallel, then after use an indicator variable, they will appear as 
N
Y
1086420
40
30
20
10
0
 
www.intechopen.com
 
Toxicity and Drug Testing 286 
shown in Figure 7. But even in this situation a general equation (or general line) might be 
used to correlate both sets of data, albeit with an increase in the regression standard 
deviation. It remained to be seen exactly how much error was introduced by use of a general 
equation.  
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Fig. 7. Plots of VOC activity, Y, against VOC carbon number, N, showing how a general 
equation may be used to correlate two sets of data that give rise to lines of different slope.  
Various sets of data on toxicological and biological activity, Y, for a number of processes were 
used to construct an equation in which a number of indicator variables, I, were used in order 
to fit all the sets of data into one equation. The result was Eqn. 51 (Abraham et al., 2010c).  
 
Y = -7.805 + 0.056 · E + 1.587 · S + 3.431· A + 1.440· B + 0.754 · L + 0.553· Idr + 
+ 2.777 ·Iodt -0.036· Inpt +  6.923· Imac + 0.440· Ird50 + 8.161· Itad + 7.437· Icon +  
+ 4.959· Idav 
       (N = 643, SD = 0.357, R2 = 0.992, F = 6083.0) 
(47)
 
The ‘standard’ process was taken as eye irritation thresholds, as log (1/EIT) for which no 
indicator variable was used. The given processes and the corresponding indicator variables 
are shown in Table 5.  
There are two processes listed in Table 5 that have not been considered here. The data on 
gaseous anesthesia on tadpoles were derived from aqueous anesthesia together with water 
to gas partition coefficients, and so are indirect data, and the compounds in the data set for 
inhalation anesthesia on mice cover a very restricted range of descriptors. Of the 720 data 
points, 77 were outliers. Nearly all of these were VOCs classed as ‘reactive’ or ‘chemical’ in 
respiratory tract irritation in mice, or VOCs that acted by specific effects in odor detection 
thresholds. The remaining 643 data points all refer to nonreactive VOCs or to VOCs that act 
through selective and not specific effects. The SD value of 0.357 in Eqn. 47 is quite good by 
comparison to the various SD values for individual processes, suggesting that the general 
equation has incorporated these with little loss in accuracy; the predicted standard deviation 
in Eqn. 47 is only 0.357 log units. The equation is scaled to eye irritation thresholds, but it is 
noteworthy that the coefficient for the NPT indicator variable is nearly zero. Thus EIT and 
NPT can be estimated through Eqn. 48 for any nonreactive VOC for which the relevant 
descriptors are available. 
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Y = log (1/EIT) = log (1/NPT) = -7.805 + 0.056 · E + 1.587 · S + 3.431· A +  
+ 1.440· B + 0.754 · L  
(48)
 
The Abraham general solvation model provides reasonably accurate mathematical 
correlations and predicitions for a number of important biological responses, including Eye 
irritation thresholds (EIT), nasal irritation (pungency) thresholds (NPT), odor detection 
thresholds (ODT) inhalation anesthesia (rats) and convulsant actictivity (mice). 
 
Activity Units Y I  VOCs 
    Total  Outliers 
Eye irritation thresholds ppm log(1/EIT)  None  23  0 
EIT from Draize scores ppm log(D/Po)  Idr  72  0 
Odor detection thresholds ppm log(1/ODT) Iodt  64 20 
Nasal pungency thresholds ppm log(1/NPT) Inpt  48  0 
Inhalation anesthesia 
( rats) 
atm log(1/MAC) Imac 147  0 
Respiratory irritation  
(mice) 
ppm log(1/RD50) Ird50 147 53 
Gaseous anesthesia (tadpoles) mol/L log(1/C) Itad 130  4 
Convulsant activity  
(rats) 
atm log(1/CON) Icon  44  0 
Inhalation anesthesia 
(mice) 
vol % log(1/vol) Idav  45  0 
Total    720 77 
Table 5. Toxicological and Biological Data on VOCs used to construct Eqn. 47  
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